NGM Biopharmaceuticals Inc expected to post a loss of 51 cents a share - Earnings Preview

NGM Biopharmaceuticals

24/02/2023 11:56

* NGM Biopharmaceuticals Inc  NGM.OQ   NGM.O  is expected
to show
a fall in quarterly revenue when it reports  results on February
27 (estimated). 
    * The South San Francisco California-based  company is
expected to
report  a 67.7% decrease in revenue to $6.764 million from
$20.96 million a year ago, according to the mean estimate from 6
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for NGM
Biopharmaceuticals
Inc is for a loss of 51 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for NGM
Biopharmaceuticals Inc is $5​, above​ its last closing price
of $4.65. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.60       -0.59      -0.59     Met     0.3
 Jun. 30 2022  -0.56       -0.55      -0.59     Missed  -7.3
 Mar. 31 2022  -0.41       -0.46      -0.42     Beat    8.3​
 Dec. 31 2021  -0.35       -0.36      -0.35     Beat    2.8
 ​​Sep.        -0.37       -0.35      -0.37     Missed  -5.7
 30 2021                                                
 Jun. 30 2021  -0.34       -0.37      -0.48     Missed  -29.1​
 Mar. 31 2021  -0.42       -0.42      -0.36     Beat    14
 Dec. 31 2020  -0.51       -0.47      -0.40     Beat    15.1
 This summary was machine generated February 24 at 11:56 GMT. 
All figures in US dollars  unless otherwise stated